Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Intact Protein Analysis at 21 Tesla and X-Ray Crystallography Define Structural Differences in Single Amino Acid Variants of Human Mitochondrial Branched-Chain Amino Acid Aminotransferase 2 (BCAT2)

Anderson, Lissa C. ; Håkansson, Maria LU ; Walse, Björn LU and Nilsson, Carol L. LU (2017) In Journal of the American Society for Mass Spectrometry 28(9). p.1796-1804
Abstract

Structural technologies are an essential component in the design of precision therapeutics. Precision medicine entails the development of therapeutics directed toward a designated target protein, with the goal to deliver the right drug to the right patient at the right time. In the field of oncology, protein structural variants are often associated with oncogenic potential. In a previous proteogenomic screen of patient-derived glioblastoma (GBM) tumor materials, we identified a sequence variant of human mitochondrial branched-chain amino acid aminotransferase 2 as a putative factor of resistance of GBM to standard-of-care-treatments. The enzyme generates glutamate, which is neurotoxic. To elucidate structural coordinates that may confer... (More)

Structural technologies are an essential component in the design of precision therapeutics. Precision medicine entails the development of therapeutics directed toward a designated target protein, with the goal to deliver the right drug to the right patient at the right time. In the field of oncology, protein structural variants are often associated with oncogenic potential. In a previous proteogenomic screen of patient-derived glioblastoma (GBM) tumor materials, we identified a sequence variant of human mitochondrial branched-chain amino acid aminotransferase 2 as a putative factor of resistance of GBM to standard-of-care-treatments. The enzyme generates glutamate, which is neurotoxic. To elucidate structural coordinates that may confer altered substrate binding or activity of the variant BCAT2 T186R, a ~45 kDa protein, we applied combined ETD and CID top-down mass spectrometry in a LC-FT-ICR MS at 21 T, and X-Ray crystallography in the study of both the variant and non-variant intact proteins. The combined ETD/CID fragmentation pattern allowed for not only extensive sequence coverage but also confident localization of the amino acid variant to its position in the sequence. The crystallographic experiments confirmed the hypothesis generated by in silico structural homology modeling, that the Lys59 side-chain of BCAT2 may repulse the Arg186 in the variant protein (PDB code: 5MPR), leading to destabilization of the protein dimer and altered enzyme kinetics. Taken together, the MS and novel 3D structural data give us reason to further pursue BCAT2 T186R as a precision drug target in GBM. [Figure not available: see fulltext.].

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Collisionally induced dissociation, Electron-transfer dissociation, High field Fourier transform mass spectrometry, High resolution, Precision medicine, Protein sequence variant, Protein structure, X Ray crystallography
in
Journal of the American Society for Mass Spectrometry
volume
28
issue
9
pages
9 pages
publisher
Elsevier
external identifiers
  • wos:000407776200007
  • pmid:28681360
  • scopus:85027397151
ISSN
1044-0305
DOI
10.1007/s13361-017-1705-0
language
English
LU publication?
yes
id
4b251376-1a1e-4f56-8a43-7c0395a86e90
date added to LUP
2017-08-29 11:02:48
date last changed
2024-03-17 19:41:14
@article{4b251376-1a1e-4f56-8a43-7c0395a86e90,
  abstract     = {{<p>Structural technologies are an essential component in the design of precision therapeutics. Precision medicine entails the development of therapeutics directed toward a designated target protein, with the goal to deliver the right drug to the right patient at the right time. In the field of oncology, protein structural variants are often associated with oncogenic potential. In a previous proteogenomic screen of patient-derived glioblastoma (GBM) tumor materials, we identified a sequence variant of human mitochondrial branched-chain amino acid aminotransferase 2 as a putative factor of resistance of GBM to standard-of-care-treatments. The enzyme generates glutamate, which is neurotoxic. To elucidate structural coordinates that may confer altered substrate binding or activity of the variant BCAT2 T186R, a ~45 kDa protein, we applied combined ETD and CID top-down mass spectrometry in a LC-FT-ICR MS at 21 T, and X-Ray crystallography in the study of both the variant and non-variant intact proteins. The combined ETD/CID fragmentation pattern allowed for not only extensive sequence coverage but also confident localization of the amino acid variant to its position in the sequence. The crystallographic experiments confirmed the hypothesis generated by in silico structural homology modeling, that the Lys59 side-chain of BCAT2 may repulse the Arg186 in the variant protein (PDB code: 5MPR), leading to destabilization of the protein dimer and altered enzyme kinetics. Taken together, the MS and novel 3D structural data give us reason to further pursue BCAT2 T186R as a precision drug target in GBM. [Figure not available: see fulltext.].</p>}},
  author       = {{Anderson, Lissa C. and Håkansson, Maria and Walse, Björn and Nilsson, Carol L.}},
  issn         = {{1044-0305}},
  keywords     = {{Collisionally induced dissociation; Electron-transfer dissociation; High field Fourier transform mass spectrometry; High resolution; Precision medicine; Protein sequence variant; Protein structure; X Ray crystallography}},
  language     = {{eng}},
  month        = {{09}},
  number       = {{9}},
  pages        = {{1796--1804}},
  publisher    = {{Elsevier}},
  series       = {{Journal of the American Society for Mass Spectrometry}},
  title        = {{Intact Protein Analysis at 21 Tesla and X-Ray Crystallography Define Structural Differences in Single Amino Acid Variants of Human Mitochondrial Branched-Chain Amino Acid Aminotransferase 2 (BCAT2)}},
  url          = {{http://dx.doi.org/10.1007/s13361-017-1705-0}},
  doi          = {{10.1007/s13361-017-1705-0}},
  volume       = {{28}},
  year         = {{2017}},
}